GCVI Summit 2018
Skip Content

6 October 2017

Merck visits Visterra to help close series C

Merck & Co and Serum Institute of India are among the investors in Visterra’s series C round, which has now closed at $46.7m following a $23.6m second tranche.

Author: Thierry Heles, Reporter

US-based antibody therapeutics developer Visterra secured $23.6m yesterday to close a series C round backed by pharmaceutical firm Merck & Co at $46.7m.